Tofacitinib: Effective Treatment for Ulcerative Colitis
Highlights of the Study:
A pragmatic prospective study assessed tofacitinib’s efficacy for moderate to severe ulcerative colitis (UC).
Intestinal ultrasound (IUS) was evaluated as a tool to distinguish responders from non-responders in real-time.
Key Findings:
• 30 adult patients started tofacitinib; most had left-sided or extensive colitis and had previously failed biologic therapy.
• At week 8, 40% showed clinical response, 20% achieved remission, and 33.3% had endoscopic healing.
• IUS accurately discriminated treatment response from non-response at week 8.
Practical Solutions and Value:
Clinical trials are crucial for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates standards and research for clinicians.
Streamlining operations is essential in healthcare. Our mobile apps support scheduling, monitoring treatments, and telemedicine, enhancing workflows and improving patient outcomes.
Reduce paper routine and manage patient care digitally with AI. Learn more at aidevmd.com.
